Form 4: Plus Therapeutics Director Lenk Reports Transaction in Company Stock
SEC Form 4 Filing
Director Robert P. Lenk reports acquisition and disposal of Plus Therapeutics (PSTV) common stock and warrants on May 8, 2024.
Summary
- On May 8, 2024, Robert P. Lenk, a director of Plus Therapeutics, Inc. (PSTV), reported a transaction involving the company's securities.
- Lenk acquired 4,167 shares of common stock at a price of $2.04 per share.
- Lenk also acquired 8,334 warrants with an exercise price of $1.79.
- Lenk disposed of 29,327 shares of common stock.
- Following the reported transactions, Lenk beneficially owns 29,327 shares of common stock and 8,334 warrants.
Sentiment
Score: 5
Explanation: This is a neutral report of insider trading activity. The acquisition and disposal of shares don't necessarily indicate a positive or negative outlook.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Stakeholder Impact
- The reported transactions may influence investor sentiment regarding Plus Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | Date of transaction: acquisition and disposal of common stock and warrants. |
| 05/08/2029 | Expiration date for 4,167 Series A warrants. |
| 05/10/2024 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Securities Exchange Act, Plus Therapeutics, PSTV, Director, Lenk, Common Stock, Warrants, Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.